Table 1.

Characteristics of calcinosis-associated SSc skin ulcers and response to Holoil® compared with a control group.

	Holoil® group n (%)	Control group n (%)	p
Patients	21	20	/
Calcinosis SU	33	26	/
Localization
Fingertips	26 (78.8)	19 (73.1)	/
Elbows	3 (9.1)	2 (7.7)	/
Knees	2 (6.1)	3 (11.6)	/
Forearms	1 (3.0)	1 (3.8)	/
Wrists	1 (3.0)	1 (3.8)	/
Shape and consistency at baseline
Stone/Plate	32 (97.0)	24 (92.3)	/
Mousse	1 (3.0)	2 (7.7)	/
Infections
S. aureus, S. maltophilia, S. hominis, E. coli	6 (18.2)	14 (53.8)	0.0058*
Antibiotic request	4 (12.1)	11 (42.3)	0.0146*
Treatment
Debridement	33 (100)	26 (100)
+ Holoil® alone	26 (78.8)	–	<0.0001*
+ Pressure on SU-cal as mousse	6 (18.2)	–	0.0297*
+ Surgical removal	1 (3.0)	6 (23.1)	0.0367*
Skin ulcer change
Healing	15 (45.4)	4 (15.4)	0.0237*
Improvement	18 (54.6)	22 (84.6)	ns
Time Healing (days)	40.1 ± 16.3	96.3 ± 10.7	0.0001*
NRS (0–10; mean ± SD)
Baseline	7.3 ± 1.9	7.5 ± 2.1	0.7506
End of follow-up	2.9 ± 1.4	4.5 ± 2.4	0.0124*
Holoil® adherence	33 (100)	–	/
Holoil® side effects (persistent erythema)	1 (3.0)	–	/

*p value < 0.05.